BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Innovations | Apr 11, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Patient sample and mouse studies suggest inhibiting adrenergic receptors , PGR , cortisol receptor GR-2 and/or CHRNB2 could help treat post-stroke Listeria monocytogenes infection. Post-stroke patients had lower numbers of circulating peripheral NK cells...
BC Innovations | Sep 25, 2014
Targets & Mechanisms

ALK7's obese functions

Reduced b- adrenergic signaling has long been associated with obesity, but the likelihood of triggering cardiovascular side effects has prevented companies from targeting the pathway for weight control. Now, a new-and possibly safer-way to upregulate...
BC Innovations | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
BC Innovations | Sep 5, 2013
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of sympathetic nervous system activation in metabolic syndrome A new mouse model could help guide development of therapies that target the sympathetic nervous...
BC Innovations | Aug 1, 2013
Targets & Mechanisms

Prostate cancer's nerves

In prostate cancer, a handful of companies are racing to develop third-generation antiandrogen therapeutics that overcome resistance mechanisms that render first- and second-generation molecules ineffective. 1,2 The problem is that any direct attack on the...
BC Innovations | Oct 20, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Adrenergic receptors; CD1D A study in mice suggests antagonizing adrenergic receptors could reduce bacterial infection after stroke. In a mouse...
BC Week In Review | Jul 25, 2011
Company News

Vicept, Allergan deal

Allergan will acquire Vicept for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a topical cream targeting alpha adrenergic receptors on small...
BC Extra | Jul 20, 2011
Company News

Allergan buying Vicept

Allergan Inc. (NYSE:AGN) will acquire dermatology company Vicept Therapeutics Inc. (Malvern, Pa.) for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a...
BC Week In Review | Apr 25, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-206 trial in 85 patients with moderate to severe erythema showed that V-101 met the primary endpoint of significantly reducing facial erythema from baseline over a 12 hour period...
Items per page:
1 - 10 of 93